89Zr-LNCab104

89Zr-LNCab104 is a **radiolabeled antibody fragment** designed for use as a diagnostic imaging agent, specifically for PET (positron emission tomography) imaging. The agent consists of an antibody fragment targeting **HER2** (human epidermal growth factor receptor 2), which is conjugated with the radioisotope **Zirconium-89 (89Zr)**. This enables visualization of HER2-expressing tumors, particularly in the context of malignant (most likely solid) tumors, including gastric cancer. As a radiopharmaceutical, 89Zr-LNCab104 allows for non-invasive PET imaging to identify and evaluate HER2-positive tumors in patients. The drug is administered intravenously, typically as a single dose of 1-3 mCi through a superficial dorsal vein, for subsequent PET imaging[5][6][9][1].